HEPSİDİN-FERROPORTİN AKSI VE COVID-19

Giriş: Viral pandemi döneminde COVID-19 tanısı almış hastalarda nötrofil, lenfosit, nötrofil-lenfosit oranı ile hemoglobin düzeylerinin, hastaların mortalite oranları, hastane yatış süreleri ve demografik özellikleri ile ilişkisinin değerlendirilmesi amacıyla yapılan bu çalışmada hepsidin-ferroportin aksının fizyopatolojideki yerinin irdelenmesi amaçlanmıştır. Gereç ve Yöntem: Hastanemiz pandemi servislerine COVID-19 tanısı ile yatan hastalar hastanemiz bilgi sisteminden taranarak hastaların laboratuar ve klinik özellikleri ile demografik bulgular analiz edilmiştir. Parametrelerin karşılaştırılmasında Independent T-test’i, one-way ANOVA ve Chi-Square kullanılıp sayı, korelasyonlar, yüzdelik, oranlar, ortalamalar ve standart sapmalar IBM SPSS Windows ver.24 ile hesaplandı. Bulgular: Çalışmaya 49 erkek ile 50 kadın hasta alınmış olup toplamda 99 hastadan oluşmaktadır. Nötrofillenfosit oranı ile hemoglobin ve yaş parametreleri arasında anlamlı bir ilişki saptandı. Başka bir deyişle yaş artıkça nötrofil-lenfosit oranında artış izlendi (r:0.347, p

HEPCIDIN-FERROPORTIN AXIS AND COVID-19

Introduction: This study was conducted to evaluate the relationship between laboratory and clinic parameters, including neutrophil, lymphocyte, neutrophil-lymphocyte ratio, hemoglobin levels, mortality, length of stay, and demographic characteristics of patients diagnosed with COVID-19 during the viral pandemic. We aimed to examine the role of the hepcidin-ferroportin axis in physiopathology. Materials and Methods: Patients hospitalized in the pandemic services of our hospital with the diagnosis of COVID-19 were scanned from the Probel electronic patient registry system, and then the laboratory parameters, clinical features with demographic findings of the patients were analyzed. In the comparison of the parameters, independent t-test, one-way ANOVA, and Chi-Square were used, and numbers, correlations, percentages, rates, averages, and standard deviations were analyzed with IBM SPSS Windows ver.24. Results: The study included 49 men and 50 women. There was a significant relationship between neutrophillymphocyte ratio with parameters of hemoglobin and age. In other words, as the age increased, an increase in the neutrophil-lymphocyte ratio was observed (r: 0.347, p: 0.000). Besides, as the neutrophil-lymphocyte ratio increased, a decrease in the level of hemoglobin was observed. As the neutrophil-lymphocyte ratio increases in patients diagnosed with COVID-19, the level of hemoglobin decreases (r: 0.232, p: 0.021). Conclusion: The negative correlation between neutrophil-lymphocyte ratio and the level of hemoglobin suggests that the hepcidin-ferroportin axis in patients with COVID-19 was affected by the cytokine storm. The determining of this statistical relationship with larger and longer studies and revealing its causes might lead to the development of effective treatment methods during the pandemic period.

PDF

___

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92(4): 401-2.
2. Hui DS, Azhar IE, Madani TA, Ntoumi F, Kock R, Dar O et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91(1): 264–6.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
4. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020; 84: 106504.
5. Pimentel GD, Dela Vega MCM, Laviano A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients. Clin Nutr ESPEN 2020; 40(1): 101-2.
6. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health 2020; 8: 152.
7. Koff WC, Williams MA. Covid-19 and Immunity in Aging Populations - A New Research Agenda. N Engl J Med 2020; 383(9): 804-5.
8. Aprahamian I, Cesari M. Geriatric Syndromes and SARS-Cov-2: More than Just Being Old. J Frailty Aging 2020; 9(3): 127-9.
9. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020; 18(1): 206.
10. Wessling-Resnick M. Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry. Annu Rev Nutr 2018; 38(1): 431-58.
11. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract 2020; 10(2): 1271.
12. 12.Ginzburg YZ. Hepcidin-ferroportin axis in health and disease. Vitam Horm 2019; 110: 17-45.
13. Liu W, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv, 6 Mar. 2020. Online. Internet. 24 Jun. 2020. Available at:https://chemrxiv.org/articles/COVID19_ Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/8.
14. Lansiaux E, Pébaÿ PP, Picard JL, Son-Forget J. COVID-19: beta-thalassemia subjects immunised?. Med Hypotheses 2020; 142(1): 109827.
15. Cao A, Galanello R, Furbetta M, Muroni PP, Garbato L, Rosatelli C. Thalassemia types and their incidences in Sardinia. J Med Genet 1979(1); 15: 443–7.
16. Siniscalco M, Bernini L, Filippi G, Latte B, Meera Khan P, Piomelli S. Population genetics of haemoglobin variants, thalassemia, and glucose-6-phosphate dehydrogenase deficiency with particular reference to the malaria hypothesis. Bull World Health Org 1966; 34(3): 379–94.
17. Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther 2020;42(2):116-117.
18. Reade MC, Weissfeld L, Angus DC, Kellum JA, Milbrandt EB. The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia. BMC Pulm Med 2010; 10(1): 15.
19. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narative review. Clin Pract 2020; 10(2): 1271.
20. De Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr 2020; 14(4): 597-600.
21. Macciò A, Madeddu C. Management of anemia of inflammation in the elderly. Anemia 2012; 2012(1) :563251.
22. Röhrig G. Anemia in the frail, elderly patient. Clin Interv Aging 2016; 11(1): 319-26.
23. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13(1): 757-72.
24. Muurlink OT, Taylor-Robinson AW. COVID-19: Cultural Predictors of Gender Differences in Global Prevalence Patterns. Front Public Health. 2020; 8(1): 174.
25. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020; 11(1): 29.
26. Demı̇r I, Guler A, Alarslan P, Isil AM, Ucman O, Aslanipour B et al. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine 2019; 65(1): 175–83.
27. Casimir GJ, Duchateau J. Gender differences in inflammatory processes could explain poorer prognosis for males. J Clin Microbiol 2011; 49(1): 478-9.